Issues facing development of new innovative medicines

Drug Information Journal

Volumn 40, Issue 3, 2006, Pages 280-289

  Yager, Jean A ^a   Starrett, Raymond ^b  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Drug advertising; Drug cost; Innovation; Patient education; Safety

Indexed keywords

CONFERENCE PAPER; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE; HIGH RISK POPULATION; MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK ASSESSMENT;

EID: 33747589916     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Tufts Center for the Study of Drug Development. Tufts CSDD Outlook 2005. Tufts University.
2. Becker GS. Economic viewpoint: new drugs cut costs, and Medicare can help. Bus Week. March 22, 2004.
3. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health. CDER 2004 Report to the Nation, Improving Human Health Through Human Drugs.
4. Pharmaceutical Research Manufacturers Association. Direct-To-Consumer Advertising Strengthens Our Healthcare System. Pharmaceutical Research Manufacturers Association.
5. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.
6. Young HN, Paterniti DA, Bell RA, Kravitz RL. Do prescription drug advertisements educate the public? The consumer answers. Drug Inf J. 2005; 39:25-33.
7. Manton KG, Gu XL. Changes in the prevalence of chronic disability in the United States black and nonblack population above age 65 from 1982 to 1999. Proc Natl Acad Sci USA. 2001;98:6354-6359.